Konruns(SH:603590)2022-04-22 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥156,191,778.75, representing a decrease of 25.99% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2022 was ¥46,436,981.84, down 27.89% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥6,884,680.06, a significant decline of 88.74%[5] - Basic and diluted earnings per share for Q1 2022 were both ¥0.30, a decrease of 26.83%[6] - In Q1 2022, the company's net profit was CNY 50,440,303.82, a decrease of 21.6% compared to CNY 64,395,066.77 in Q1 2021[22] - The total revenue from operating activities was CNY 235,245,392.87, down 10.5% from CNY 262,836,445.33 in the same period last year[25] - The company's total comprehensive income for Q1 2022 was CNY 31,295,350.69, compared to a loss of CNY 67,892,684.49 in Q1 2021[23] Cash Flow and Assets - The net cash flow from operating activities increased by 82.23%, amounting to ¥57,190,059.97[5] - Cash and cash equivalents as of March 31, 2022, were RMB 538,783,262.66, down from RMB 599,081,775.25 at the end of 2021[15] - The cash and cash equivalents at the end of Q1 2022 were CNY 826,389,336.17, down from CNY 962,851,329.42 at the end of Q1 2021[27] - Total assets at the end of the reporting period were ¥3,362,120,574.65, a slight decrease of 0.27% from the end of the previous year[6] - Total assets as of March 31, 2022, were RMB 3,362,120,574.65, a slight decrease from RMB 3,371,320,206.37 at the end of 2021[18] Expenses and Liabilities - Total operating costs for Q1 2022 were RMB 127,527,189.83, down from RMB 142,364,608.25 in Q1 2021, reflecting a cost reduction strategy[21] - Sales expenses in Q1 2022 amounted to RMB 71,535,482.12, a decrease of 23% from RMB 93,320,858.76 in Q1 2021[21] - Research and development expenses for Q1 2022 were RMB 16,729,400.94, slightly up from RMB 16,068,231.02 in Q1 2021, indicating continued investment in innovation[21] - Total liabilities decreased to RMB 198,424,463.66 as of March 31, 2022, compared to RMB 240,742,477.76 at the end of 2021[18] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 1.01% to ¥2,917,879,941.58[6] - The company's equity attributable to shareholders increased to RMB 2,917,879,941.58 as of March 31, 2022, from RMB 2,888,764,881.18 at the end of 2021[18] Non-Recurring Gains and Future Outlook - The decline in net profit after deducting non-recurring gains was primarily due to the new medical insurance negotiation price for "Su Ling," leading to reduced sales prices and revenue impacts from the ongoing pandemic[10] - The company reported non-recurring gains totaling ¥39,552,301.78 after tax, with significant contributions from government subsidies and other non-operating income[9] - The company reported a net profit margin improvement due to cost control measures, although specific profit figures were not disclosed[21] - Future outlook includes a focus on market expansion and potential new product launches, although specific details were not provided in the report[21] Investment and Tax - The company reported an investment loss of CNY 114,983,877.92 in Q1 2022, compared to a loss of CNY 101,677,003.56 in Q1 2021[26] - The company incurred interest expenses of CNY 208,726.16 in Q1 2022, compared to CNY 358,055.88 in Q1 2021, reflecting a decrease of 41.7%[22] - The company reported a tax expense of CNY 3,907,909.27 in Q1 2022, down from CNY 8,720,966.12 in Q1 2021, indicating a decrease of 55.2%[22] - The company paid CNY 49,286,660.61 in employee compensation during Q1 2022, an increase from CNY 33,763,839.98 in Q1 2021[26]